Daclizumab reduces risk of renal transplant rejection

Gespeichert in:

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	1999

Schlagwörter:	Acute Rejection Triple Therapy Daclizumab Dual Therapy Antithymocyte Globulin

Anmerkung:	© Adis International Ltd 1999

Übergeordnetes Werk:	Enthalten in: Inpharma weekly - Auckland : ADIS internat., 1975, 1203(1999), 1 vom: Sept., Seite 12-12
Übergeordnetes Werk:	volume:1203 ; year:1999 ; number:1 ; month:09 ; pages:12-12

Links:	Volltext

DOI / URN:	10.2165/00128413-199912030-00021

Katalog-ID:	SPR036287105

Internformat


LEADER	01000caa a22002652 4500
001	SPR036287105
003	DE-627
005	20230519130015.0
007	cr uuu---uuuuu
008	201007s1999 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2165/00128413-199912030-00021 \|2 doi
035			\|a (DE-627)SPR036287105
035			\|a (SPR)00128413-199912030-00021-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Daclizumab reduces risk of renal transplant rejection
264		1	\|c 1999
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Adis International Ltd 1999
650		4	\|a Acute Rejection \|7 (dpeaa)DE-He213
650		4	\|a Triple Therapy \|7 (dpeaa)DE-He213
650		4	\|a Daclizumab \|7 (dpeaa)DE-He213
650		4	\|a Dual Therapy \|7 (dpeaa)DE-He213
650		4	\|a Antithymocyte Globulin \|7 (dpeaa)DE-He213
773	0	8	\|i Enthalten in \|t Inpharma weekly \|d Auckland : ADIS internat., 1975 \|g 1203(1999), 1 vom: Sept., Seite 12-12 \|w (DE-627)373977859 \|w (DE-600)2127607-9 \|x 2230-6056 \|7 nnns
773	1	8	\|g volume:1203 \|g year:1999 \|g number:1 \|g month:09 \|g pages:12-12
856	4	0	\|u https://dx.doi.org/10.2165/00128413-199912030-00021 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
951			\|a AR
952			\|d 1203 \|j 1999 \|e 1 \|c 09 \|h 12-12

Indexfelder

matchkey_str	article:22306056:1999----::alzmbeuersornlrn
hierarchy_sort_str	1999
publishDate	1999
allfields	10.2165/00128413-199912030-00021 doi (DE-627)SPR036287105 (SPR)00128413-199912030-00021-e DE-627 ger DE-627 rakwb eng Daclizumab reduces risk of renal transplant rejection 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1999 Acute Rejection (dpeaa)DE-He213 Triple Therapy (dpeaa)DE-He213 Daclizumab (dpeaa)DE-He213 Dual Therapy (dpeaa)DE-He213 Antithymocyte Globulin (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1203(1999), 1 vom: Sept., Seite 12-12 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1203 year:1999 number:1 month:09 pages:12-12 https://dx.doi.org/10.2165/00128413-199912030-00021 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1203 1999 1 09 12-12
spelling	10.2165/00128413-199912030-00021 doi (DE-627)SPR036287105 (SPR)00128413-199912030-00021-e DE-627 ger DE-627 rakwb eng Daclizumab reduces risk of renal transplant rejection 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1999 Acute Rejection (dpeaa)DE-He213 Triple Therapy (dpeaa)DE-He213 Daclizumab (dpeaa)DE-He213 Dual Therapy (dpeaa)DE-He213 Antithymocyte Globulin (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1203(1999), 1 vom: Sept., Seite 12-12 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1203 year:1999 number:1 month:09 pages:12-12 https://dx.doi.org/10.2165/00128413-199912030-00021 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1203 1999 1 09 12-12
allfields_unstemmed	10.2165/00128413-199912030-00021 doi (DE-627)SPR036287105 (SPR)00128413-199912030-00021-e DE-627 ger DE-627 rakwb eng Daclizumab reduces risk of renal transplant rejection 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1999 Acute Rejection (dpeaa)DE-He213 Triple Therapy (dpeaa)DE-He213 Daclizumab (dpeaa)DE-He213 Dual Therapy (dpeaa)DE-He213 Antithymocyte Globulin (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1203(1999), 1 vom: Sept., Seite 12-12 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1203 year:1999 number:1 month:09 pages:12-12 https://dx.doi.org/10.2165/00128413-199912030-00021 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1203 1999 1 09 12-12
allfieldsGer	10.2165/00128413-199912030-00021 doi (DE-627)SPR036287105 (SPR)00128413-199912030-00021-e DE-627 ger DE-627 rakwb eng Daclizumab reduces risk of renal transplant rejection 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1999 Acute Rejection (dpeaa)DE-He213 Triple Therapy (dpeaa)DE-He213 Daclizumab (dpeaa)DE-He213 Dual Therapy (dpeaa)DE-He213 Antithymocyte Globulin (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1203(1999), 1 vom: Sept., Seite 12-12 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1203 year:1999 number:1 month:09 pages:12-12 https://dx.doi.org/10.2165/00128413-199912030-00021 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1203 1999 1 09 12-12
allfieldsSound	10.2165/00128413-199912030-00021 doi (DE-627)SPR036287105 (SPR)00128413-199912030-00021-e DE-627 ger DE-627 rakwb eng Daclizumab reduces risk of renal transplant rejection 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1999 Acute Rejection (dpeaa)DE-He213 Triple Therapy (dpeaa)DE-He213 Daclizumab (dpeaa)DE-He213 Dual Therapy (dpeaa)DE-He213 Antithymocyte Globulin (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1203(1999), 1 vom: Sept., Seite 12-12 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1203 year:1999 number:1 month:09 pages:12-12 https://dx.doi.org/10.2165/00128413-199912030-00021 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1203 1999 1 09 12-12
language	English
source	Enthalten in Inpharma weekly 1203(1999), 1 vom: Sept., Seite 12-12 volume:1203 year:1999 number:1 month:09 pages:12-12
sourceStr	Enthalten in Inpharma weekly 1203(1999), 1 vom: Sept., Seite 12-12 volume:1203 year:1999 number:1 month:09 pages:12-12
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Acute Rejection Triple Therapy Daclizumab Dual Therapy Antithymocyte Globulin
isfreeaccess_bool	false
container_title	Inpharma weekly
publishDateDaySort_date	1999-09-01T00:00:00Z
hierarchy_top_id	373977859
id	SPR036287105
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036287105</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519130015.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1999 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-199912030-00021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036287105</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-199912030-00021-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Daclizumab reduces risk of renal transplant rejection</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 1999</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Rejection</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Triple Therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Daclizumab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dual Therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antithymocyte Globulin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1203(1999), 1 vom: Sept., Seite 12-12</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1203</subfield><subfield code="g">year:1999</subfield><subfield code="g">number:1</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:12-12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-199912030-00021</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1203</subfield><subfield code="j">1999</subfield><subfield code="e">1</subfield><subfield code="c">09</subfield><subfield code="h">12-12</subfield></datafield></record></collection>
ppnlink_with_tag_str_mv	@@773@@(DE-627)373977859
format	electronic Article
delete_txt_mv	keep
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2230-6056
topic_title	Daclizumab reduces risk of renal transplant rejection Acute Rejection (dpeaa)DE-He213 Triple Therapy (dpeaa)DE-He213 Daclizumab (dpeaa)DE-He213 Dual Therapy (dpeaa)DE-He213 Antithymocyte Globulin (dpeaa)DE-He213
topic	misc Acute Rejection misc Triple Therapy misc Daclizumab misc Dual Therapy misc Antithymocyte Globulin
spellingShingle	misc Acute Rejection misc Triple Therapy misc Daclizumab misc Dual Therapy misc Antithymocyte Globulin Daclizumab reduces risk of renal transplant rejection
topic_unstemmed	misc Acute Rejection misc Triple Therapy misc Daclizumab misc Dual Therapy misc Antithymocyte Globulin
topic_browse	misc Acute Rejection misc Triple Therapy misc Daclizumab misc Dual Therapy misc Antithymocyte Globulin
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Inpharma weekly
hierarchy_parent_id	373977859
hierarchy_top_title	Inpharma weekly
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)373977859 (DE-600)2127607-9
title	Daclizumab reduces risk of renal transplant rejection
ctrlnum	(DE-627)SPR036287105 (SPR)00128413-199912030-00021-e
title_full	Daclizumab reduces risk of renal transplant rejection
journal	Inpharma weekly
journalStr	Inpharma weekly
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	1999
contenttype_str_mv	txt
container_start_page	12
container_volume	1203
format_se	Elektronische Aufsätze
doi_str_mv	10.2165/00128413-199912030-00021
title_sort	daclizumab reduces risk of renal transplant rejection
title_auth	Daclizumab reduces risk of renal transplant rejection
abstract	© Adis International Ltd 1999
abstractGer	© Adis International Ltd 1999
abstract_unstemmed	© Adis International Ltd 1999
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20
container_issue	1
title_short	Daclizumab reduces risk of renal transplant rejection
url	https://dx.doi.org/10.2165/00128413-199912030-00021
remote_bool	true
ppnlink	373977859
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.2165/00128413-199912030-00021
up_date	2024-07-03T16:56:35.818Z
_version_	1803577768878800896
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036287105</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519130015.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1999 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-199912030-00021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036287105</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-199912030-00021-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Daclizumab reduces risk of renal transplant rejection</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 1999</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Rejection</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Triple Therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Daclizumab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dual Therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antithymocyte Globulin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1203(1999), 1 vom: Sept., Seite 12-12</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1203</subfield><subfield code="g">year:1999</subfield><subfield code="g">number:1</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:12-12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-199912030-00021</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1203</subfield><subfield code="j">1999</subfield><subfield code="e">1</subfield><subfield code="c">09</subfield><subfield code="h">12-12</subfield></datafield></record></collection>
score	7.399641

Nicht das Richtige dabei?

Schreiben Sie uns!

Daclizumab reduces risk of renal transplant rejection

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?